Clinical Trial Update: An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex [Phase 2]

View source ↗

Summary

Phase 2 efficacy study evaluating oral didanosine (ddI) in zidovudine-intolerant patients with AIDS or AIDS-related complex; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Videx (didanosine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED